Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Early treatment may improve outcomes in Shwachman-Diamond syndrome (opens in a new tab)

news-medical.net · 2026-09-23

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 9Not checkedMore than 90% of children born with Shwachman-Diamond syndrome survive beyond age 20, but fewer than 30% live beyond age 50.View evidenceHide evidence

As statedmore than 90%; fewer than 30%

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 9Not checkedA study published Sept. 23, 2026, in The New England Journal of Medicine suggests that longer-term survival could be improved by intervening earlier on signs of high risk in Shwachman-Diamond syndrome.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 9Not checkedThe article says the findings suggest hematopoietic cell transplants, sometimes in patients aged 14 and younger, should occur shortly after detecting high-risk features such as mutated bone marrow cell clones or progressive dysplasias, rather than waiting for MDS or AML.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 9Not checkedThe study was co-led by Kasiani Myers, MD, with co-authors from the International SDS Research Consortium.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 9Not checkedThe international team assembled the largest known collection of SDS outcome data, based on 847 cases ranging from infancy to beyond age 50.View evidenceHide evidence

As stated847 cases

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 6 of 9Not checkedThe article says the cumulative risks of MDS, AML, and bone marrow failure were nearly 78% by age 50, while the incidence of potentially lethal malignancies was as low as 2% for 5-year-olds.View evidenceHide evidence

As statednearly 78% by age 50; 2% for 5-year-olds

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 7 of 9Not checkedAmong 24 high-risk patients, nearly 82% were alive at two years after HCT, compared with 55% if MDS had already been diagnosed and 36% if AML had already arisen.View evidenceHide evidence

As stated82%; 55%; 36%

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 8 of 9Not checkedThe co-authors state that the data support surveillance and early HCT for patients who develop high-risk features to preempt malignancy.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 9 of 9Not checkedThe article notes that more research is needed to determine the ideal age and risk factors for moving forward with HCT and whether alternative therapies can be developed.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Cumulative Hematologic Morbidity and Outcomes in Shwachman–Diamond Syndrome

New England Journal of Medicine · 2026

Source record (opens in a new tab)

Why this one

Confident

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Selected

Cumulative Hematologic Morbidity and Outcomes in Shwachman–Diamond Syndrome

New England Journal of Medicine · 2026 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.